as a small pharmaceutical development company, Aptar, a leading global manufacturer of inhalers, is our sole supplier for supply of its intranasal Unit Dose Spray product, or UDS, to be the delivery …
Nasus Pharma Ltd. Customers
No clients on recordNo downstream customers found in our database for Nasus Pharma Ltd..
Nasus Pharma Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
NSRX-DEBT
Debt stack $118,000
90%
Market cache reports total debt of $118,000.
NSRX-DEBT-17124
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Nasus Pharma Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Nasus Pharma Ltd..
Nasus Pharma Ltd. Ownership
Holder
Name
Confidence
Evidence
NSRX-OWNER-MORGAN-STANLEY
Morgan Stanley
95%
13F/ownership overlay lists Morgan Stanley; shares held 2,000; ownership 0.02%; value $4,420; as of 2025-12-31.
NSRX-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 378; value $835; as of 2025-12-31.
NSRX-OWNER-BALYASNY-ASSET-MANAGEMENT-L-P
Balyasny Asset Management L.P.
90%
13F overlay lists Balyasny Asset Management L.P. as top holder; 9 tracked holders.
